Search Results - "Morecki, S"

Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses by Morecki, S, Gelfand, Y, Yacovlev, E, Eizik, O, Shabat, Y, Sagiv, I, Slavin, S

“…Selective elimination of alloreactive cells was carried out in the set-up of T-cell-mediated immunotherapy in an effort to gain the benefits of hematopoietic…”
Get full text

Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen by MORECKI, S, GELFAND, Y, NAGLER, A, OR, R, NAPARSTEK, E, VARADI, G, ENGELHARD, D, AKERSTEIN, A, SLAVIN, S

“…We have investigated the immune status of patients with hematologic malignancies treated with a low intensity conditioning in preparation for allogeneic stem…”
Get full text

Effect of KRN7000 on induced graft-vs-host disease by Morecki, Shoshana, Panigrahi, Soumya, Pizov, Galina, Yacovlev, Elena, Gelfand, Yael, Eizik, Osnat, Slavin, Shimon

“…Graft-vs-host disease (GVHD) is a serious complication of allogeneic stem cell transplantation (SCT) and donor lymphocyte infusion (DLI), for which no…”
Get full text

Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes by SLAVIN, S, ACKERSTEIN, A, MORECKI, S, GELFAND, Y, CIVIDALLI, G

“…Allogeneic cell-mediated immunotherapy with donor lymphocyte infusion (DLI) can successfully reverse chemoradiotherapy-resistant relapse in patients with…”
Get full text

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma by Morecki, S., Moshel, Y., Gelfend, Y., Pugatsch, T., Slavin, S.

“…We have attempted to induce immune‐mediated graft‐vs.‐tumor (GVT) effects against solid tumors, using a murine model of mammary adenocarcinoma derived from…”
Get full text

Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma by Morecki, S., Yacovlev, L., Slavin, S.

“…Indomethacin, an inhibitor of cyclo‐oxygenase given orally, reduced the tumorigenicity of cancer cells in a non‐immunogenic murine model of mammary…”
Get full text

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma by Morecki, S, Yacovlev, E, Gelfand, Y, Uzi, I, Slavin, S

“…Cell therapy with allogeneic donor cells mismatched for minor histocompatible (MiHC) antigens was applied to a murine mammary carcinoma (4T1) model to test the…”
Get full text

Lymphocytes as Cellular Vehicles for Gene Therapy in Mouse and Man by Culver, Kenneth, Cornetta, Kenneth, Morgan, Rick, Morecki, Shoshana, Aebersold, Paul, Kasid, Attan, Lotze, Michael, Rosenberg, Steven A., Anderson, W. French, Blaese, R. Michael

“…The application of bone marrow gene therapy has been stalled by the inability to achieve stable high-level gene transfer and expression in the totipotent stem…”
Get full text

Human Gene Transfer: Characterization of Human Tumor-Infiltrating Lymphocytes as Vehicles for Retroviral-Mediated Gene Transfer in Man by Kasid, Attan, Morecki, Shoshana, Aebersold, Paul, Cornetta, Kenneth, Culver, Kenneth, Freeman, Scott, Director, Elaine, Lotze, Michael T., Blaese, R. Michael, Anderson, W. French, Rosenberg, Steven A.

“…Tumor-infiltrating lymphocytes (TILs) are cells generated from tumor suspensions cultured in interleukin 2 that can mediate cancer regression when adoptively…”
Get full text

Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning by Aiuti, Alessandro, Slavin, Shimon, Aker, Memet, Ficara, Francesca, Deola, Sara, Mortellaro, Alessandra, Morecki, Shoshana, Andolfi, Grazia, Tabucchi, Antonella, Carlucci, Filippo, Marinello, Enrico, Cattaneo, Federica, Vai, Sergio, Servida, Paolo, Miniero, Roberto, Roncarolo, Maria Grazia, Bordignon, Claudio

“…Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy…”
Get full text

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation by Kapelushnik, J, Nagler, A, Or, R, Naparstek, E, Ackerstein, A, Samuel, S, Morecki, S, Nabet, C, Slavin, S

“…We describe a 17-year-old male patient with chronic myelogenous leukemia (CML) in hematologic and cytogenetic relapse 4 months post-non-T cell-depleted…”
Get more information

Alloantigen persistence in induction and maintenance of transplantation tolerance by MORECKI, S, LESHEM, B, EID, A, SLAVIN, S

“…Infusion of parental bone marrow cells into F1 hybrids conditioned by total lymphoid irradiation (TLI) results in chimeras with a high percentage of donor-type…”
Get full text

Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1) by Morecki, S, Nagler, A, Zakay-Rones, Z, Schlesinger, M, Lubina-Salomon, A, Pugatsch, T, Moshel, Y, Slavin, S

“…Multiple injections of intact irradiated BCL1 cells, a murine B-cell leukemia/lymphoma can trigger a dose-dependent anti-tumor immune response in naive…”
Get full text

The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells by Morecki, S, Nabet, C, Ackerstein, A, Schlesinger, M, Slavin, S

“…The effect of immunocompetent lymphocyte depletion on precursors and effector cells of IL2 activated non-MHC restricted cytotoxic cells (LAK) generated from…”
Get more information

Purging breast cancer cells in preparation for autologous bone marrow transplantation by Morecki, S, Pavlotzky, F, Margel, S, Slavin, S

“…Mixtures of the T-47D human breast cancer cell line and normal human bone marrow cells were used for studying a new approach for purging epithelial tumor cells…”
Get more information

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes by Morecki, Shoshana, Lindhofer, Horst, Yacovlev, Elena, Gelfand, Yael, Slavin, Shimon

“…A trifunctional bispecific antibody (BiLu) directed against murine CD3 and human epithelial-cell adhesion molecule (EpCAM) was tested for its ability to…”
Get full text

Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction by Weigensberg, M, Morecki, S, Weiss, L, Fuks, Z, Slavin, S

“…Total lymphoid irradiation (TLI) was administered to (BALB/c X C57BL/6)F1 mice in eight daily doses of 200 rad (total 1600 rad). Spleen cells isolated from…”
Get full text

Prevention and treatment of relapse by bone marrow transplantation by Slavin, S, Weiss, L, Ackerstein, A, Vourka-Karussis, U, Morecki, S, Or, R, Nagler, A, Kapelushnik, J, Delukina, M, Drakos, P

“…High, myeloablative doses of chemoradiotherapy represent the treatment of choice for a large number of malignant hematological diseases that cannot be…”
Get more information

The use of parabiosis for investigating the mechanism of transplantation tolerance in bone marrow chimeras induced by total lymphoid irradiation by Eid, A, Morecki, S, Slavin, S

“…The mechanism of transplantation tolerance in total lymphoid irradiation (TLI)-induced semiallogeneic bone marrow chimeras without clinical evidence of…”
Get more information

Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation by Weiss, L, Morecki, S, Vitetta, ES, Slavin, S

“…Mice carrying the B cell leukemia (BCL1)+ were successfully treated by total lymphoid irradiation (TLI), cyclophosphamide, and allogeneic bone marrow (BM)…”
Get full text